Driscoll D F, Lawrence K R, Lewis K, Bistrian B R
Department of Pharmacy; and Faculty, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA.
Int J Pharm Compd. 1997 Mar-Apr;1(2):118-20.
The Centers for Disease Control has identified intravenous propofol, a lipid-based medication, as a cause of postoperative infections in hospitalized patients. It appears the increased risk results from poor aseptic technique in the preparation, storage and administration of extemporaneously prepared propofol infusions. An additional risk of preparing propofol injection includes glass particulate contamination when the ampule dosage form is used. The current study, therefore, examines the extrinsic particulate load between propofol syringes prepared from ampules and vials with and without the use of a filter needle. Ten operating room clinicians were asked to prepare propofol infusion from ampules using a standard needle and a special filter needle. A similar comparison was performed separately in the laboratory using propofol vials to deduce differences between the normal presence of fat globules and the adventitious introducion of glass particulates from propofol ampules. Partical size analysis was determined by a single-particle, optical-sensing device using laser light extinction. Aliquots of the unfiltered and filtered samples were analyzed in triplicate by number-weighting all particles greater than or equal to 1.75 micrometers (instrument threshold for detecting abnormal particles) and all particles > 5 micrometers and >10 micrometers (theoretical physiologic threshold for producing embolic syndrome). Significant differences were noted between dosage forms with respect to the number of particulates present from the pre- to the postfiltrate samples. A reduction in very large particulates (>10 micrometers) was observed from the ampules (P=0.034). No differences were noted for the smaller particles (>1.75 micrometers,p= 0.333; >5 micrometers, p=0.229). Of the propofol vial samples, no differences were noted for the larger particles (>5 micrometers, p=0.575; >10 micrometers, p=0.229). However. a significant increase in the number of particle size was noted for the smallest particles (>1.75 micrometers, p=0.0001). This increase in the numbler of particles in the postfiltrate may reflect the effects of filtration in destabilizing lipid particles. The use of the 5 micrometer filter needle significantly reduced the amount of abnormally large particles (>10 micrometers) from the ampule dosage form, whereas no difference was observed from the propofol vials. This implies the abnormal particles present were other than lipid and likely to be glass associated with ampule breakage, suggesting the 5 micrometer filter needle be a standard part of propofol therapy when preparing infusions from ampule dosage forms.
美国疾病控制中心已确定静脉注射丙泊酚(一种脂质类药物)是住院患者术后感染的一个原因。术后感染风险增加似乎是由于临时配制丙泊酚输注液在制备、储存和给药过程中无菌技术不佳所致。配制丙泊酚注射液的另一个风险是使用安瓿剂型时会出现玻璃微粒污染。因此,本研究检测了使用和不使用过滤针头从安瓿和药瓶中制备的丙泊酚注射器之间的外在微粒负荷。10名手术室临床医生被要求分别使用标准针头和特殊过滤针头从安瓿中制备丙泊酚输注液。在实验室中,使用丙泊酚药瓶进行了类似的比较,以推断脂肪球正常存在与丙泊酚安瓿中偶然引入玻璃微粒之间的差异。通过使用激光消光的单颗粒光学传感装置测定颗粒大小分析。对未过滤和过滤后的样品等分试样进行三次分析,对所有大于或等于1.75微米(检测异常颗粒的仪器阈值)以及所有大于5微米和大于10微米(产生栓塞综合征的理论生理阈值)的颗粒进行数量加权。就预过滤和后过滤样品中存在的颗粒数量而言,不同剂型之间存在显著差异。从安瓿中观察到非常大的颗粒(>10微米)数量减少(P=0.034)。对于较小的颗粒(>1.75微米,P=0.333;>5微米,P=0.229),未观察到差异。在丙泊酚药瓶样品中,对于较大的颗粒(>5微米,P=0.575;>10微米,P=0.229),未观察到差异。然而,对于最小的颗粒(>1.75微米,P=0.0001),颗粒数量显著增加。后过滤样品中颗粒数量的增加可能反映了过滤对脂质颗粒稳定性的影响。使用5微米过滤针头可显著减少安瓿剂型中异常大颗粒(>10微米)的数量,而在丙泊酚药瓶中未观察到差异。这意味着存在的异常颗粒不是脂质,可能是与安瓿破裂相关的玻璃微粒,这表明在从安瓿剂型制备输注液时,5微米过滤针头应成为丙泊酚治疗的标准组成部分。